Human Molecular Genetics, 2001, Vol. 10, No. 16 1649-1656
© 2001 Oxford University Press
The importance of gene dosage studies: mutational analysis of the parkin gene in early-onset parkinsonism
1Department of Neurology and 2Department of Human Genetics, Medical University of Lübeck, Ratzeburger Allee 160, 23538 Lübeck, Germany, 3Department of Hematology, Regional General Hospital, 39100 Bolzano, Italy, 4TIB MOLBIOL, 10829 Berlin, Germany, 5Division of Neurology, Department of Medicine, University of Toronto, and Toronto Western Hospital, Toronto M5T 2S8, Canada, 6Molecular Neurogenetics Unit, Massachusetts General Hospital, and Departments of Neurology and Neuroscience Program, Harvard Medical School, Boston, MA 02129, USA, 7Molecular Genetics, Albert Einstein College of Medicine, Bronx, NY 10461, USA and 8Department of Neurology, Regional General Hospital, 39100 Bolzano, Italy
Early-onset parkinsonism (EOP) may be associated with different mutations in the parkin gene, including exon deletions and duplications. To test for gene dosage alterations, we developed a new method of quantitative duplex PCR using the fluorescence resonance energy transfer technique on the LightCycler (Roche Diagnostics). In 21 patients with EOP, three mutations (a single base pair substitution in exon 3 and small deletions in exon 9) were detected by conventional mutational screening (single-strand conformation polymorphism and sequence analysis), while alterations of gene dosage were found in seven patients. We identified heterozygous and compound heterozygous deletions of exons 2, 3, 5 and 7. The latter was also found in the homozygous state. In addition, two heterozygous duplications of exon 4 were observed. Remarkably, two patients carried more than two parkin mutations. This is the first study systematically screening all 12 exons of parkin by real-time, kinetic quantification and clearly shows that mutational analysis of the parkin gene should include gene dosage studies. Furthermore, our method of quantitative PCR is easily applicable to any other gene to be screened for deletions or duplications of whole exons.
+ To whom correspondence should be addressed. Tel: +49 451 500 2993; Fax: +49 451 500 4861; Email: klein_ch@neuro.mu-luebeck.de The authors wish it to be known that, in their opinion, the first two authors should be regarded as joint First Authors
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
C. Klein and M. G. Schlossmacher Parkinson disease, 10 years after its genetic revolution: Multiple clues to a complex disorder Neurology, November 27, 2007; 69(22): 2093 - 2104. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Asmus, L. E. Hjermind, E. Dupont, J. Wagenstaller, E. Haberlandt, M. Munz, T. M. Strom, and T. Gasser Genomic deletion size at the epsilon-sarcoglycan locus determines the clinical phenotype Brain, October 1, 2007; 130(10): 2736 - 2745. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Hampe, H. Ardila-Osorio, M. Fournier, A. Brice, and O. Corti Biochemical analysis of Parkinson's disease-causing variants of Parkin, an E3 ubiquitin-protein ligase with monoubiquitylation capacity Hum. Mol. Genet., July 1, 2006; 15(13): 2059 - 2075. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Sun, J. C. Latourelle, G. F. Wooten, M. F. Lew, C. Klein, H. A. Shill, L. I. Golbe, M. H. Mark, B. A. Racette, J. S. Perlmutter, et al. Influence of heterozygosity for parkin mutation on onset age in familial Parkinson disease: the GenePD study. Arch Neurol, June 1, 2006; 63(6): 826 - 832. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Klein Implications of genetics on the diagnosis and care of patients with Parkinson disease. Arch Neurol, March 1, 2006; 63(3): 328 - 334. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Deng, W.-D. Le, C. B. Hunter, W. G. Ondo, Y. Guo, W.-J. Xie, and J. Jankovic Heterogeneous Phenotype in a Family With Compound Heterozygous Parkin Gene Mutations Arch Neurol, February 1, 2006; 63(2): 273 - 277. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Buhmann, F. Binkofski, C. Klein, C. Buchel, T. van Eimeren, C. Erdmann, K. Hedrich, M. Kasten, J. Hagenah, G. Deuschl, et al. Motor reorganization in asymptomatic carriers of a single mutant Parkin allele: a human model for presymptomatic parkinsonism Brain, October 1, 2005; 128(10): 2281 - 2290. [Abstract] [Full Text] [PDF] |
||||
![]() |
B Schule, N Kock, M Svetel, N Dragasevic, K Hedrich, P de Carvalho Aguiar, L Liu, K Kabakci, J Garrels, E-M Meyer, et al. Genetic heterogeneity in ten families with myoclonus-dystonia J. Neurol. Neurosurg. Psychiatry, August 1, 2004; 75(8): 1181 - 1185. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Costa, J.-M. Jouannic, N. Stieltjes, J.-M. Costa, E. Girodon, and M. Goossens Quantitative Real-Time PCR Assay for Rapid Identification of Deletion Carriers in Hemophilia Clin. Chem., July 1, 2004; 50(7): 1269 - 1270. [Full Text] [PDF] |
||||
![]() |
I. F. Mata, P. J. Lockhart, and M. J. Farrer Parkin genetics: one model for Parkinson's disease Hum. Mol. Genet., April 1, 2004; 13(90001): R127 - 133. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Hedrich, A. Djarmati, N. Schafer, R. Hering, C. Wellenbrock, P. H. Weiss, R. Hilker, P. Vieregge, L. J. Ozelius, P. Heutink, et al. DJ-1 (PARK7) mutations are less frequent than Parkin (PARK2) mutations in early-onset Parkinson disease Neurology, February 10, 2004; 62(3): 389 - 394. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kabakci, K. Hedrich, J. C. Leung, M. Mitterer, P. Vieregge, R. Lencer, J. Hagenah, J. Garrels, K. Witt, F. Klostermann, et al. Mutations in DYT1: Extension of the phenotypic and mutational spectrum Neurology, February 10, 2004; 62(3): 395 - 400. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. F. Winklhofer, I. H. Henn, P. C. Kay-Jackson, U. Heller, and J. Tatzelt Inactivation of Parkin by Oxidative Stress and C-terminal Truncations: A PROTECTIVE ROLE OF MOLECULAR CHAPERONES J. Biol. Chem., November 21, 2003; 278(47): 47199 - 47208. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Pankratz, W. C. Nichols, S. K. Uniacke, C. Halter, J. Murrell, A. Rudolph, C. W. Shults, P. M. Conneally, T. Foroud, and the Parkinson Study Group Genome-wide linkage analysis and evidence of gene-by-gene interactions in a sample of 362 multiplex Parkinson disease families Hum. Mol. Genet., October 16, 2003; 12(20): 2599 - 2608. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Klein, K. Hedrich, K. Kabakci, K. Mohrmann, K. Wiegers, O. Landt, J. Hagenah, E. Schwinger, P. P. Pramstaller, L. J. Ozelius, et al. Exon deletions in the GCHI gene in two of four Turkish families with dopa-responsive dystonia Neurology, December 10, 2002; 59(11): 1783 - 1786. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kann, K. Hedrich, P. Vieregge, H. Jacobs, B. Muller, N. Kock, E. Schwinger, C. Klein, K. Marder, J. Harris, et al. The parkin gene is not involved in late-onset Parkinson's disease Neurology, March 12, 2002; 58(5): 835 - 835. [Full Text] [PDF] |
||||
![]() |
S. van Soest, J. Swart, N. Tijmes, L. A. Sandkuijl, J. Rommers, and A. A.B. Bergen A Locus for Autosomal Recessive Pseudoxanthoma Elasticum, with Penetrance of Vascular Symptoms in Carriers, Maps to Chromosome 16p13.1 Genome Res., August 1, 1997; 7(8): 830 - 834. [Abstract] [Full Text] [PDF] |
||||







